Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics grows market share ahead of key trial results

Interim revenues at the hay fever vaccine specialist rose by 4% to £42.2mln
Girl
Results from two trials are due this year

Allergy Therapeutics plc (LON:AGY) made further market share gains as it headed into a ‘pivotal’ twelve months.

Interim revenues at the hay fever vaccine specialist rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.

WATCH: 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

Pollinex’s market share in Germany, its core market, rose one point to 14%, while bee and wasp sting product Venomil and Acarovac in Spain sold well.

Profits eased slightly to £6.03mln (£7.2mln) as Allergy increased R&D spending as two clinical trials moved into critical stages.

Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial. 

That trial is especially important said Manuel Llobet, chief executive, as it “provides us the platform to expand into the lucrative US market”.

Spending on the trials will peak in the second half of the year, which will double the first half’s £5.9mln R&D costs.

Net sales of the existing products are again expected to run ahead of the market in the second half.

“Our continued focus on new product development is illustrated by our work on Polyvac Peanut,” added Llobet.

“Whilst at an early stage, we believe that our well-established, innovative approach to immunising patients from allergy symptoms could provide a new approach to combating this severe affliction.”

Cash at the end of the period was £25.8mln.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use